Increase in SARS-CoV-2 RBD-Specific IgA and IgG Antibodies in Human Milk From Lactating Women Following the COVID-19 Booster Vaccination
BACKGROUND: The United States Centers for Disease Control and Prevention recommended a third dose or booster of the Pfizer-BioNTech Comirnaty (BNT162b2) COVID-19 mRNA vaccine in September 2021 for high-risk individuals. Pregnant and high-risk lactating women were encouraged to receive the booster to obtain potential prolonged protection for themselves and their infants.
RESEARCH AIM: To investigate the ability of the booster vaccine to increase IgA and IgG antibodies specific to the receptor-binding domain of the SARS-CoV-2 spike protein in human milk compared to levels pre-booster.
METHODS: This was a prospective one-group study with a pretest-posttest design. Six of 12 participants were recruited prospectively. Participants were instructed to collect ≥ 2 ounces of milk in the morning at 30 days and 1-day pre-booster, and 7, 14, 21, 30, 45, and 60 days post-booster. Levels of IgA and IgG antibodies specific to the receptor-binding domain of the SARS-CoV-2 spike protein were quantified in human milk via an ELISA assay.
RESULTS: We found a significant increase in anti-receptor-binding domain-specific IgA and IgG antibodies in human milk 1-2 weeks after the Pfizer-BioNTech booster and at the study endpoint (45- and 60-days post-booster).
CONCLUSIONS: This suggests that the booster vaccination enhances SARS-CoV-2 specific immunity in human milk, which may be protective for infants.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Journal of human lactation : official journal of International Lactation Consultant Association - 39(2023), 1 vom: 28. Feb., Seite 51-58 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Henle, Andrea M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.02.2023 Date Revised 21.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/08903344221134631 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349121672 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349121672 | ||
| 003 | DE-627 | ||
| 005 | 20231226041851.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/08903344221134631 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1163.xml |
| 035 | |a (DE-627)NLM349121672 | ||
| 035 | |a (NLM)36398916 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Henle, Andrea M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Increase in SARS-CoV-2 RBD-Specific IgA and IgG Antibodies in Human Milk From Lactating Women Following the COVID-19 Booster Vaccination |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2023 | ||
| 500 | |a Date Revised 21.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: The United States Centers for Disease Control and Prevention recommended a third dose or booster of the Pfizer-BioNTech Comirnaty (BNT162b2) COVID-19 mRNA vaccine in September 2021 for high-risk individuals. Pregnant and high-risk lactating women were encouraged to receive the booster to obtain potential prolonged protection for themselves and their infants | ||
| 520 | |a RESEARCH AIM: To investigate the ability of the booster vaccine to increase IgA and IgG antibodies specific to the receptor-binding domain of the SARS-CoV-2 spike protein in human milk compared to levels pre-booster | ||
| 520 | |a METHODS: This was a prospective one-group study with a pretest-posttest design. Six of 12 participants were recruited prospectively. Participants were instructed to collect ≥ 2 ounces of milk in the morning at 30 days and 1-day pre-booster, and 7, 14, 21, 30, 45, and 60 days post-booster. Levels of IgA and IgG antibodies specific to the receptor-binding domain of the SARS-CoV-2 spike protein were quantified in human milk via an ELISA assay | ||
| 520 | |a RESULTS: We found a significant increase in anti-receptor-binding domain-specific IgA and IgG antibodies in human milk 1-2 weeks after the Pfizer-BioNTech booster and at the study endpoint (45- and 60-days post-booster) | ||
| 520 | |a CONCLUSIONS: This suggests that the booster vaccination enhances SARS-CoV-2 specific immunity in human milk, which may be protective for infants | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a IgA and IgG Antibodies in Human Milk | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a United States | |
| 650 | 4 | |a booster | |
| 650 | 4 | |a breastfeeding | |
| 650 | 4 | |a immunology | |
| 650 | 4 | |a lactation | |
| 650 | 4 | |a passive immunity | |
| 650 | 4 | |a vaccination | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a Immunoglobulin A |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of human lactation : official journal of International Lactation Consultant Association |d 1995 |g 39(2023), 1 vom: 28. Feb., Seite 51-58 |w (DE-627)NLM012692794 |x 1552-5732 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2023 |g number:1 |g day:28 |g month:02 |g pages:51-58 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/08903344221134631 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2023 |e 1 |b 28 |c 02 |h 51-58 | ||